AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32766953 — intervention group
Group type: COMPARATOR
Intervention: Apixaban ≥ 48 h (Late group)
Number of subjects: 686
Study 32766953 — intervention group
Group type: EXPERIMENTAL
Intervention: Early group
Number of subjects: 686
Study 32766961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor
Number of subjects: 25
Study 32766961 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 25
Study 32767054 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS monitoring during surgery
Number of subjects: 49
Study 32767054 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGE scale assessment
Number of subjects: 49
Study 32767054 — intervention group
Group type: EXPERIMENTAL
Intervention: Time required for NIRS data collection
Number of subjects: 49
Study 32767153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome analysis in STC group
Number of subjects: 0
Study 32767153 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFA concentration analysis in STC group
Number of subjects: 0
Study 32767153 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for Acetate
Number of subjects: 0
Study 32767153 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for Propionate
Number of subjects: 0
Study 32767153 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for gut microbiome
Number of subjects: 0
Study 32767153 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of Ruminococcus
Number of subjects: 0
Study 32767153 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of Roseburia
Number of subjects: 0
Study 32767659 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) containing DNA (EV-DNA)
Number of subjects: 0
Study 32767659 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-DNA in clinical settings
Number of subjects: 0
Study 32767997 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4
Number of subjects: 1100
Study 32767997 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1100
Study 32767997 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart disease
Number of subjects: 1100
Study 32767997 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 1100
Study 32767997 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 1100
Study 32768158 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 Gy SIB-IMRT
Number of subjects: 9
Study 32768179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding leading to a postoperative haemoglobin <70 g L
Number of subjects: 16079
Study 32768179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding meeting predefined screening criteria
Number of subjects: 16079
Study 32768540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to the common peroneal nerve (geko™)
Number of subjects: 8
Study 32769075 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing and self-administered tests of functional mobility and strength
Number of subjects: 10
Study 32769075 — intervention group
Group type: COMPARATOR
Intervention: Videoconference
Number of subjects: 10
Study 32769075 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote assessment test protocol
Number of subjects: 10
Study 32769736 — intervention group
Group type: EXPERIMENTAL
Intervention: MINIject
Number of subjects: 31
Study 32769752 — intervention group
Group type: EXPERIMENTAL
Intervention: IOLMaster 700 (biometer A)
Number of subjects: 209
Study 32769773 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce risk of opioid overdose following discharge from the Emergency Department
Number of subjects: 0
Study 32769773 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32769835 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinjury psychiatric history
Number of subjects: 1158
Study 32769835 — intervention group
Group type: EXPERIMENTAL
Intervention: History of prior TBI
Number of subjects: 1158
Study 32769835 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-TBI symptoms (measured by Rivermead Post-Concussion Symptoms Questionnaire)
Number of subjects: 1158
Study 32770263 — intervention group
Group type: EXPERIMENTAL
Intervention: CA6 rs17032907 gene variant
Number of subjects: 200
Study 32770263 — intervention group
Group type: EXPERIMENTAL
Intervention: CA6 rs17032907 gene variant (dominant model CC vs. TT)
Number of subjects: 200
Study 32770263 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype CC and allele C presence
Number of subjects: 200
Study 32770443 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one, virtual/online intervention delivery
Number of subjects: 0
Study 32770443 — intervention group
Group type: COMPARATOR
Intervention: Traditional group-based format
Number of subjects: 0
Study 32770466 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern respondents
Number of subjects: 299
Study 32770466 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 299
Study 32770466 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who routinely tested patients prior to surgery
Number of subjects: 299
Study 32770466 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers not fully dedicated to COVID-19 care
Number of subjects: 299
Study 32770704 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a rectal balloon catheter alongside the AAR catheter
Number of subjects: 35
Study 32770720 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab at 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) in dose escalation; flat doses of 250 mg Q2W or 500 mg every four weeks (Q4W) in multihistology expansion cohort.
Number of subjects: 59
Study 32770720 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab at 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) in dose escalation.
Number of subjects: 59
Study 32770720 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab at various doses.
Number of subjects: 59
Study 32770720 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab in both Japanese and Western patients.
Number of subjects: 59
Study 32770845 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation conducted by a pharmacist
Number of subjects: 1884
Study 32770845 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on identified risk factors
Number of subjects: 1884
Study 32770946 — intervention group
Group type: EXPERIMENTAL
Intervention: GP empathy assessed using The Care Measure (CARE)
Number of subjects: 93
Study 32770946 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Enablement Instrument (PEI)
Number of subjects: 93
Study 32770946 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check consultation leading to lifestyle change
Number of subjects: 93
Study 32770954 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct sampling following a specific respiratory manoeuvre
Number of subjects: 0
Study 32770954 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect sampling during passive respiratory activity
Number of subjects: 0
Study 32770954 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 0
Study 32770954 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TB chemotherapy
Number of subjects: 0
Study 32771020 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RT) intervention, eighteen 1-h sessions
Number of subjects: 10
Study 32771060 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI) derived from PET/MRI
Number of subjects: 90
Study 32771088 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg orally twice daily for 4 weeks, followed by olaparib 300 mg twice daily and durvalumab 1.5 g intravenously every 4 weeks until disease progression.
Number of subjects: 34
Study 32771088 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and durvalumab combination treatment.
Number of subjects: 34
Study 32771575 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress CMR with evidence of ischemia or late gadolinium enhancement (LGE)
Number of subjects: 582
Study 32771575 — intervention group
Group type: COMPARATOR
Intervention: No CMR evidence of ischemia or LGE
Number of subjects: 582
Study 32771685 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Test
Number of subjects: 0
Study 32771685 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32771997 — intervention group
Group type: EXPERIMENTAL
Intervention: Portico device via subclavian/axillary access
Number of subjects: 45
Study 32772073 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% O2 group
Number of subjects: 1125
Study 32772073 — intervention group
Group type: COMPARATOR
Intervention: 20% O2 group (atmospheric O2)
Number of subjects: 1125
Study 32772323 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TTh) for 27.63 ± 3.64 weeks
Number of subjects: 15
Study 32772323 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TTh)
Number of subjects: 15
Study 32772323 — intervention group
Group type: COMPARATOR
Intervention: Untreated hypogonadal men (n=46)
Number of subjects: 15
Study 32772323 — intervention group
Group type: COMPARATOR
Intervention: Eugonadal men (n=17)
Number of subjects: 15
Study 32772680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke participants
Number of subjects: 86
Study 32772680 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 86
Study 32772769 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells therapy
Number of subjects: 17
Study 32772863 — intervention group
Group type: EXPERIMENTAL
Intervention: French adaptation of the Family Relationship Index (FRI)
Number of subjects: 1657
Study 32773243 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV (live, attenuated, tetravalent dengue vaccine)
Number of subjects: 0
Study 32773348 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE programming
Number of subjects: 3528
Study 32773348 — intervention group
Group type: COMPARATOR
Intervention: No ADVANCE programming (control)
Number of subjects: 3528
Study 32773366 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrive by Three intervention
Number of subjects: 1531
Study 32773366 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1531
Study 32773376 — intervention group
Group type: EXPERIMENTAL
Intervention: Work2Prevent (W2P) employment intervention program
Number of subjects: 56
Study 32773383 — intervention group
Group type: EXPERIMENTAL
Intervention: Work2Prevent (W2P) intervention, specifically the iFOUR program adapted for youth, aimed at increasing job-seeking self-efficacy and career readiness.
Number of subjects: 21
Study 32773383 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews and focus groups with YMSM, YTW, and GNC youth.
Number of subjects: 21
Study 32773383 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interviews with LGBTQ-inclusive employers.
Number of subjects: 21
Study 32773447 — intervention group
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for Injection (DAXI) 40U, up to 3 treatments over a maximum of 84 weeks
Number of subjects: 2691
Study 32773474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir 800 mg once daily and etravirine 400 mg once daily or 200 mg twice daily
Number of subjects: 15
Study 32773964 — intervention group
Group type: EXPERIMENTAL
Intervention: FoodImage smartphone app
Number of subjects: 24
Study 32773964 — intervention group
Group type: COMPARATOR
Intervention: Weighed diaries
Number of subjects: 24
Study 32773964 — intervention group
Group type: COMPARATOR
Intervention: Visually estimated diaries
Number of subjects: 24
Study 32774184 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive tools for quantifying microcirculatory function; specific dosage and duration not available.
Number of subjects: 0
Study 32774184 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive pressure measurements; specific dosage and duration not available.
Number of subjects: 0
Study 32774419 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Spa Therapy using Therapeutic Radon-Sulfur Waters
Number of subjects: 0
Study 32774419 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32774889 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy (PT) including proprioceptive neuromuscular facilitation (PNF) techniques, endurance training, and individually indicated interventions (5 to 9 sessions over 3 to 4 weeks).
Number of subjects: 20
Study 32774889 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no specific intervention mentioned.
Number of subjects: 20
Study 32775606 — intervention group
Group type: EXPERIMENTAL
Intervention: New ACOMI/non-ACOMI ECG approach
Number of subjects: 3000
Study 32775606 — intervention group
Group type: COMPARATOR
Intervention: Non-STEMI group
Number of subjects: 3000
Study 32775606 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention in patients with non-ACO-predicting ECGs
Number of subjects: 3000
Study 32775822 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 17
Study 32775974 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath samples from patients with NAFLD cirrhosis
Number of subjects: 43
Study 32775974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dimethyl sulfide and D-limonene
Number of subjects: 43
Study 32775974 — intervention group
Group type: COMPARATOR
Intervention: Breath samples from healthy volunteers
Number of subjects: 43
Study 32775985 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 44
Study 32775985 — intervention group
Group type: COMPARATOR
Intervention: Paricalcitol
Number of subjects: 44
Study 32776135 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing Klebsiella pneumoniae sequence type 101 isolated from clinical samples and food (poultry)
Number of subjects: 3
Study 32776159 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride multilayer extended-release capsules (MPH-MLR) at doses of 10, 15, or 20 mg
Number of subjects: 10
Study 32776309 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive mothers
Number of subjects: 125
Study 32776402 — intervention group
Group type: EXPERIMENTAL
Intervention: Val/Val group from the rs6265, BDNF
Number of subjects: 218
Study 32776402 — intervention group
Group type: COMPARATOR
Intervention: Met allele groups
Number of subjects: 218
Study 32776402 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF rs6265
Number of subjects: 218
Study 32776402 — intervention group
Group type: EXPERIMENTAL
Intervention: Val/Val phenotype of BDNF
Number of subjects: 218
Study 32776489 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment (n=10)
Number of subjects: 24
Study 32776489 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (n=14)
Number of subjects: 24
Study 32776489 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (aPCC and/or rFVIIa)
Number of subjects: 24
Study 32776632 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg daily and Sorafenib 200 mg twice daily
Number of subjects: 17
Study 32776990 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockdown situation
Number of subjects: 0
Study 32776990 — intervention group
Group type: COMPARATOR
Intervention: Perceived stress and anxiety
Number of subjects: 0
Study 32776990 — intervention group
Group type: EXPERIMENTAL
Intervention: Boredom and sadness
Number of subjects: 0
Study 32776990 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger and fear of death
Number of subjects: 0
Study 32777064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (4 mg on days 1, 8, and 15 of a 28-day cycle, started on day +5)
Number of subjects: 25
Study 32777064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 25
Study 32777116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/d for 21 days in combination with idarubicin and cytarabine chemotherapy
Number of subjects: 33
Study 32777335 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Gy single-dose radiation therapy (SDRT)
Number of subjects: 292
Study 32778047 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive vascular unloading technique (Nexfin®)
Number of subjects: 60
Study 32778047 — intervention group
Group type: COMPARATOR
Intervention: Semi-invasive pulse contour analysis reference method (FloTrac™)
Number of subjects: 60
Study 32778059 — intervention group
Group type: EXPERIMENTAL
Intervention: My Tools 4 Care - In Care (MT4C-In Care)
Number of subjects: 280
Study 32778059 — intervention group
Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 280
Study 32778061 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted, contrast-enhanced MRI for detection of liver metastases
Number of subjects: 0
Study 32778061 — intervention group
Group type: COMPARATOR
Intervention: Follow-up imaging with paired CT and MRI at 3-, 6-, and 12-months as an alternative reference standard
Number of subjects: 0
Study 32778081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater reliability assessment using inclinometer for seated and standing upper thoracic spine posture
Number of subjects: 32
Study 32778081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater reliability assessment using measuring tape for TS posture
Number of subjects: 32
Study 32778081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater reliability assessment using manual assessment for segmental extension
Number of subjects: 32
Study 32778081 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability assessment using inclinometer for standing and seated upper TS posture
Number of subjects: 32
Study 32778081 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability assessment using inclinometer for standing whole TS posture
Number of subjects: 32
Study 32778081 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of intra-rater and inter-rater reliability
Number of subjects: 32
Study 32778081 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of posture measurements with an inclinometer
Number of subjects: 32
Study 32778081 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of manual assessments
Number of subjects: 32
Study 32778095 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg BID followed by olaparib + durvalumab (1500 mg Q4W) + tremelimumab (75 mg IV Q4W) for 4 months, then durvalumab alone until progression or intolerable toxicity.
Number of subjects: 213
Study 32778118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mollii® suit used for 6 weeks
Number of subjects: 20
Study 32778146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 201
Study 32778146 — intervention group
Group type: COMPARATOR
Intervention: Non-Dexmedetomidine (non-DEX)
Number of subjects: 201
Study 32778555 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care coverage in states with expanded Medicaid
Number of subjects: 0
Study 32778555 — intervention group
Group type: COMPARATOR
Intervention: No health care coverage
Number of subjects: 0
Study 32778748 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 0
Study 32778827 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 56
Study 32778912 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic biopsy (SBx) in addition to targeted biopsy (TBx)
Number of subjects: 384
Study 32778912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on MRI volumetric parameters and clinical information
Number of subjects: 384
Study 32779037 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior neoadjuvant/adjuvant trastuzumab (NAT)
Number of subjects: 287
Study 32779037 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo MBC patients
Number of subjects: 287
Study 32779077 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-lesion level CCTA measures
Number of subjects: 1297
Study 32779077 — intervention group
Group type: COMPARATOR
Intervention: Per-patient level CCTA measures
Number of subjects: 1297
Study 32779077 — intervention group
Group type: COMPARATOR
Intervention: Model 1 (adjusted only by clinical risk factors)
Number of subjects: 1297
Study 32779077 — intervention group
Group type: COMPARATOR
Intervention: Comparison of per-lesion versus per-patient analysis
Number of subjects: 1297
Study 32779571 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention (digital)
Number of subjects: 2909
Study 32779571 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention with face-to-face group coaching (F2F+digital)
Number of subjects: 2909
Study 32779571 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 2909
Study 32779573 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART program (stepped-care eHealth HIV prevention program)
Number of subjects: 1285
Study 32779705 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion
Number of subjects: 12
Study 32779730 — intervention group
Group type: COMPARATOR
Intervention: Targeted client communication via mobile devices (TCCMD)
Number of subjects: 26854
Study 32779863 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (subcutaneous daily injections starting at 2 mg/kg, increased up to 6 mg/kg if fever persisted)
Number of subjects: 16
Study 32779863 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 16
Study 32779947 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD monitored at days 33 and 90
Number of subjects: 0
Study 32780021 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer debriefing
Number of subjects: 28
Study 32780021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no debriefing)
Number of subjects: 28
Study 32780026 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTrack intervention (clinical pharmacist-led mobile health approach)
Number of subjects: 15
Study 32780519 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 32780600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency vital-sign monitoring
Number of subjects: 0